Trane Technologies plc (TT)
After hours:
| Previous Close | 332.92 |
| Open | 334.27 |
| Bid | 331.92 x 800 |
| Ask | 340.00 x 800 |
| Day's Range | 331.14 - 335.28 |
| 52 Week Range | 162.04 - 335.28 |
| Volume | |
| Avg. Volume | 953,111 |
| Market Cap | 75.144B |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | 35.13 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.36 (1.01%) |
| Ex-Dividend Date | Jun 07, 2024 |
| 1y Target Est | N/A |
- Business Wire
Range Energy and Thermo King Collaborate to Advance the Commercial Adoption of Electric Refrigerated Trailers in the Americas
MOUNTAIN VIEW, Calif. & MINNEAPOLIS, May 09, 2024--Range Energy (Range), the hardware company bringing powered trailers to the commercial trucking market, and Thermo King, a leader in sustainable transport temperature control solutions and strategic brand of Trane Technologies (NYSE: TT), today announced a strategic collaboration to advance the commercialization of electric refrigerated trailers in the Americas.
- ACCESSWIRE
Trane Technologies and the U.S. Department of Energy Partner To Advance Building Decarbonization in New Heat Pump Technology Challenge
Following its industry-leading performance in the DOE's Residential Cold Climate Heat Pump Challenge, company brings its expertise to commercial heat pump challenge SWORDS, IRELAND / ACCESSWIRE / May 8, 2024 / Trane Technologies (NYSE:TT), a global ...
- PR Newswire
Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma
Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).
